Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

InMed Pharmaceuticals (INM) Equity Ratio (2021 - 2025)

Historic Equity Ratio for InMed Pharmaceuticals (INM) over the last 5 years, with Q4 2025 value amounting to 0.86.

  • InMed Pharmaceuticals' Equity Ratio rose 1782.17% to 0.86 in Q4 2025 from the same period last year, while for Dec 2025 it was 0.86, marking a year-over-year increase of 1782.17%. This contributed to the annual value of 0.86 for FY2025, which is 1073.79% up from last year.
  • Per InMed Pharmaceuticals' latest filing, its Equity Ratio stood at 0.86 for Q4 2025, which was up 1782.17% from 0.87 recorded in Q3 2025.
  • InMed Pharmaceuticals' Equity Ratio's 5-year high stood at 0.88 during Q3 2021, with a 5-year trough of 0.88 in Q3 2023.
  • Over the past 5 years, InMed Pharmaceuticals' median Equity Ratio value was 0.82 (recorded in 2024), while the average stood at 0.71.
  • Its Equity Ratio has fluctuated over the past 5 years, first tumbled by 21623.65% in 2023, then surged by 19144.04% in 2024.
  • InMed Pharmaceuticals' Equity Ratio (Quarter) stood at 0.73 in 2021, then increased by 15.92% to 0.85 in 2022, then decreased by 1.18% to 0.84 in 2023, then fell by 13.15% to 0.73 in 2024, then grew by 17.82% to 0.86 in 2025.
  • Its Equity Ratio was 0.86 in Q4 2025, compared to 0.87 in Q3 2025 and 0.86 in Q2 2025.